Affiliation:
1. The National Medical Research Center for Endocrinology
Abstract
Oncogenic osteomalacia is an orphan disease caused by the overproduction of fibroblast growth factor 23 (FGF23) in tumors, which leads to impaired bone matrix mineralization. Typical laboratory changes are hypophosphatemia, increased alkaline phosphatase, hyperphosphaturia, and decreased tubular phosphate reabsorption index. Surgery is the treatment of choice to eliminate an excessive production of FGF23. If surgical intervention is ineffective or impossible, preparations of phosphorus, calcium, vitamin D are prescribed. We present a clinical case of the stage-bystage diagnosis and treatment of the patient with chronic pain syndrome in the bones and multiple fractures.
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference20 articles.
1. Bhatt AA, Mathews SS, Kumari A, Paul TV. Tumour-induced osteomalacia. Hong Kong Med J. 2014;20(4):350.e1-2. doi: 10.12809/hkmj133981
2. Popova IYu, Grebennikova TA, Tiulpakov AN, Kulikova KS, Rozhinskaya LY, Belaya ZE. Rare genetic diseases of the bone tissue: the case of a family with osteogenesis imperfecta and X-linked hypophosphataemia. Osteoporosis and Bone Diseases. 2018;21(1):2833 (In Russ.). doi: 10.14341/osteo9756
3. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. 2001;284(4):977-981. doi: 10.1006/bbrc.2001.5084
4. Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. 2021;108(1):128-142. doi: 10.1007/s00223-020-00691-6
5. Bulycheva IV, Bliznyukov OP, Rodionova SS, Buklemishev YE, Belaya ZhE. Oncogenic osteomalacia/phosphaturic mesenchymal tumor. Clinical observation. Literature review. Bone and Soft Tissue Sarcomas, Tumors of the Skin. 2019;1:28-32 (In Russ.).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献